Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Purpose: The core features of dementia with Lewy bodies (DLB) are cognitive fluctuations, visual hallucinations, and parkinsonian symptoms. Although there have been several reports on the efficacy of treatments for psychotic symptoms in patients with DLB, little is known regarding the treatment effects of aripiprazole. The aim of this study was to evaluate the efficacy and safety of aripiprazole for the treatment of psychotic symptoms in patients with DLB. Patients and methods: We employed a 10-week, open-label study design with 11 patients who met the criteria for DLB. The patients had previously experienced persistent or intermittent delusions, hallucinations, or both for at least 1 month. Aripiprazole was initiated at a low dose (3 or 6 mg/day) and titrated to higher doses at 2-week intervals or more rapidly, as needed. The Neuropsychiatric Inventory (NPI), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression-Severity (CGI-S) were administered at baseline and 1, 2, 4, 8, and 10 weeks later. The Simpson–Angus Scale (SAS), Clinical Dementia Rating (CDR), and Mini-Mental State Examination (MMSE) Scale were evaluated at baseline and at week 10. The NPI, CGI-S, and BPRS scores were compared between the baseline and each assessment point and between each assessment point and the one before assessment point. The SAS, CDR, and MMSE scores were compared between the baseline and the end point. Results: The mean NPI and BPRS scores improved until the fourth week; they significantly decreased at each assessment point compared to the previous one. Afterward, improvements slowed and continued without significant decrease. The median SAS scores significantly decreased at the end point compared to the baseline ( P <0.05). The median MMSE score was higher at the end point than at the baseline ( P <0.05). Conclusion: This study showed that aripiprazole may be effective and well tolerated for the treatment of psychotic symptoms in patients with DLB. Keywords: aripiprazole, Lewy bodies, dementia, psychotic symptoms
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among antipsychotics, aripiprazole was reported in a small study to be effective and well tolerated for the treatment of psychotic symptoms in patients with dementia with Lewy bodies 126 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
McKeith, I. G. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s347 · Cited by 625
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
DeLeon, A., Patel, N. C., & Lynn Crismon, M. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 363
Donepezil for dementia with Lewy bodies: A randomized, placebo‐controlled trial
Mori, E., Ikeda, M., Kosaka, K., & on behalf of the Donepezil‐DLB Study Investigators (2012) · Annals of Neurology · doi:10.1002/ana.23557 · Cited by 274
Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria
Aarsland, D., Rongve, A., Piepenstock Nore, S., Skogseth, R., Skulstad, S., Ehrt, U., Hoprekstad, D., & Ballard, C. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000165917 · Cited by 208
Mintzer, J. E., Tune, L. E., Breder, C. D., Swanink, R., Marcus, R. N., McQuade, R. D., & Forbes, A. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181557b47 · Cited by 172
De Deyn, P., Jeste, D. V., Swanink, R., Kostic, D., Breder, C., Carson, W. H., & Iwamoto, T. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000178415.22309.8f · Cited by 150
Streim, J. E., Porsteinsson, A. P., Breder, C. D., Swanink, R., Marcus, R. N., McQuade, R. D., & Carson, W. H. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318165db77 · Cited by 126
Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience
Fernandez, H. H., Trieschmann, M. E., & Friedman, J. H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200401000-00003 · Cited by 121
Risperidone for psychotic and behavioural symptoms in Lewy body dementia
Allen, R. L., Walker, Z., D’Ath, P., & Katona, C. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91245-2 · Cited by 80
Takahashi, H., Yoshida, K., Sugita, T., Higuchi, H., & Shimizu, T. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00040-x · Cited by 74
Self-citationAntipsychotic treatments for the elderly: efficacy and safety of aripiprazole
Kohen, I., Lester, P. E., & Lam, S. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s6411 · Cited by 48
Kim, S.-W., Shin, I.-S., Kim, J.-M., Lee, J.-H., Lee, Y.-H., Yang, S.-J., & Yoon, J.-S. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31819a68b5 · Cited by 47
Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia
Riedel, M. J., Spellmann, I., Schennach-Wolff, R., Musil, R., Dehning, S., Cerovecki, A., Opgen-Rhein, M., Matz, J., Seemüller, F., Obermeier, M., et al. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1239539 · Cited by 46
Suzuki, H., Gen, K., & Inoue, Y. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.021 · Cited by 42
The use of risperidone, an atypical neuroleptic, in lewy body disease
Lee, H., Cooney, J. M., & LAWLOR, B. A. (1994) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930090511 · Cited by 41
The pattern of psychiatric disorders among the aged in a selected community in Nigeria
Uwakwe, R. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(200004)15:4<355::aid-gps126>3.0.co;2-8 · Cited by 37
Cognitive-enhancing effects of aripiprazole: a case report
Mucci, A., Piegari, G., & Galderisi, S. (2008) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-4-24 · Cited by 12
Cited by
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Magierski, R., Sobow, T., Schwertner, E., & Religa, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01168 · Cited by 118
Systematic review of pharmacological interventions for people with Lewy body dementia
Watts, K. E., Storr, N. J., Barr, P. G., & Rajkumar, A. P. (2022) · Aging & Mental Health · doi:10.1080/13607863.2022.2032601 · Cited by 41
Erskine, D., & Taylor, J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00856-7 · Cited by 19
Chu, C.-S., Yang, F.-C., Tseng, P.-T., Stubbs, B., Dag, A., Carvalho, A. F., Thompson, T., Tu, Y.-K., Yeh, T.-C., Li, D.-J., et al. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104474 · Cited by 14
Metadata
- Authors
- Sugawara Kikuchi, Y., & Shimizu, T.
- Affiliations
- Akita University (JP)
- Corresponding author
- Shimizu, Tetsuo
- ORCID
- Shimizu, Tetsuo
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2019-02
- Volume
- Volume 15
- Pages
- 543-547
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC6390858
- OpenAlex
- W2916859458
- Cited by
- 14
- References
- 21
- Citations by year
- 2025: 3 · 2024: 2 · 2022: 5 · 2021: 2 · 2020: 1 · 2019: 1
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- aripiprazole, dementia with Lewy bodies, psychotic symptoms, delusions, hallucinations, antipsychotic drugs, treatment efficacy, drug safety, cognitive function, neuropsychiatric symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.